Pivotal Trial to Evaluate the Safety and Effectiveness of the P&F TricValve® Transcatheter Bicaval Valve System
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- P+F Products + Features USA Inc.
- Study ID
- NCT06458907
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cardiovascular Diseases
- Heart Failure
- Heart Valve Diseases
- Tricuspid Valve Disease
- Tricuspid Valve Insufficiency
- Tricuspid Valve Regurgitation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- TricValve System — DEVICE• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy
- Optimal medical therapy — DRUGOptimal medical therapy
Study Details
Pivotal trial to evaluate the safety and effectiveness of the P\&F TricValve® Transcatheter Bicaval Valve System.
Key Dates
- Start date
- Apr 30, 2026
- Status verified
- May 2026
- Primary completion
- Nov 30, 2028
- Completion
- Nov 30, 2032
Study Design
- Enrollment
- 780 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: TricValve System + Optimal medical therapy (OMT)Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy (OMT) in patients with caval reflux and tricuspid regurgitation.
- Active Comparator: Optimal medical therapy (OMT) AloneOMT alone in patients with caval reflux and tricuspid regurgitation
- Experimental: TricValve Single Arm RegistrySingle-Arm Registry for Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with OMT in patients with caval reflux and tricuspid regurgitation who are not eligible for randomization
Primary Outcome Measure
Randomized Cohort: Caval Reflux (CR) grade reduction [ Time Frame: 6 months ]
Central Contacts
- Thuy Olender+1 408-839-3809
Locations (35)
Find similar trials in Birmingham, AL
By condition
By specialty
Related Studies
- Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsRecruiting · Medtronic · Birmingham, Alabama
- TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)Recruiting · Brigham and Women's Hospital · Boston, Massachusetts
- Identification of Genomic Predictors of Adverse Events After Cardiac SurgeryRecruiting · Brigham and Women's Hospital · Boston, Massachusetts
- Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft TissuesRecruiting · Arunark Kolipaka · Columbus, Ohio